These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 26851799)

  • 1. Blood Eosinophils and Outcomes in Severe Hospitalized Exacerbations of COPD.
    Bafadhel M; Greening NJ; Harvey-Dunstan TC; Williams JE; Morgan MD; Brightling CE; Hussain SF; Pavord ID; Singh SJ; Steiner MC
    Chest; 2016 Aug; 150(2):320-8. PubMed ID: 26851799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eosinophils in COPD Exacerbations Are Associated With Increased Readmissions.
    Couillard S; Larivée P; Courteau J; Vanasse A
    Chest; 2017 Feb; 151(2):366-373. PubMed ID: 27746201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eosinophil counts in first COPD hospitalizations: a comparison of health service utilization.
    Bélanger M; Couillard S; Courteau J; Larivée P; Poder TG; Carrier N; Girard K; Vézina FA; Vanasse A
    Int J Chron Obstruct Pulmon Dis; 2018; 13():3045-3054. PubMed ID: 30319252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The utility of inflammatory markers to predict readmissions and mortality in COPD cases with or without eosinophilia.
    Duman D; Aksoy E; Agca MC; Kocak ND; Ozmen I; Akturk UA; Gungor S; Tepetam FM; Eroglu SA; Oztas S; Karakurt Z
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2469-78. PubMed ID: 26648709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort.
    Hastie AT; Martinez FJ; Curtis JL; Doerschuk CM; Hansel NN; Christenson S; Putcha N; Ortega VE; Li X; Barr RG; Carretta EE; Couper DJ; Cooper CB; Hoffman EA; Kanner RE; Kleerup E; O'Neal WK; Paine R; Peters SP; Alexis NE; Woodruff PG; Han MK; Meyers DA; Bleecker ER;
    Lancet Respir Med; 2017 Dec; 5(12):956-967. PubMed ID: 29146301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood eosinophils and treatment response in hospitalized exacerbations of chronic obstructive pulmonary disease: A case-control study.
    Serafino-Agrusa L; Scichilone N; Spatafora M; Battaglia S
    Pulm Pharmacol Ther; 2016 Apr; 37():89-94. PubMed ID: 26996272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood eosinophils as predictor of outcomes in patients hospitalized for COPD exacerbations: a prospective observational study.
    Kostikas K; Papathanasiou E; Papaioannou AI; Bartziokas K; Papanikolaou IC; Antonakis E; Makou I; Hillas G; Karampitsakos T; Papaioannou O; Dimakou K; Apollonatou V; Verykokou G; Papiris S; Bakakos P; Loukides S
    Biomarkers; 2021 Jun; 26(4):354-362. PubMed ID: 33724121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High eosinophil blood counts are associated with a shorter length of hospital stay in exacerbated COPD patients - a retrospective analysis.
    Greulich T; Tüffers J; Mager S; Eder A; Maxheim M; Alter P; Schmeck B; Vogelmeier CF
    Respir Res; 2020 May; 21(1):106. PubMed ID: 32375777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the clinical characteristics and treatment outcomes of patients requiring hospital admission to treat eosinophilic and neutrophilic exacerbations of COPD.
    Kang HS; Rhee CK; Kim SK; Kim JW; Lee SH; Yoon HK; Ahn JH; Kim YH
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2467-2473. PubMed ID: 27757029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association between eosinophilic exacerbation and eosinophilic levels in stable COPD.
    Kang HS; Kim SK; Kim YH; Kim JW; Lee SH; Yoon HK; Rhee CK
    BMC Pulm Med; 2021 Mar; 21(1):74. PubMed ID: 33653314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study.
    Brightling CE; Bleecker ER; Panettieri RA; Bafadhel M; She D; Ward CK; Xu X; Birrell C; van der Merwe R
    Lancet Respir Med; 2014 Nov; 2(11):891-901. PubMed ID: 25208464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-IL-5 therapies for chronic obstructive pulmonary disease.
    Donovan T; Milan SJ; Wang R; Banchoff E; Bradley P; Crossingham I
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013432. PubMed ID: 33295032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Study of the role of blood eosinophil count in patients with severe acute exacerbation of chronic obstructive pulmonary disease hospitalized in a Tunisian Center].
    Saad AB; Khemakhem R; Mhamed SC; Fahem N; Migaou A; Joobeur S; Rouatbi N
    Pan Afr Med J; 2019; 34():138. PubMed ID: 33708307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COPD exacerbation phenotypes in a real-world five year hospitalisation cohort.
    Jones TPW; Brown J; Hurst JR; Vancheeswaran R; Brill S
    Respir Med; 2020 Jun; 167():105979. PubMed ID: 32421545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low and High Blood Eosinophil Counts as Biomarkers in Hospitalized Acute Exacerbations of COPD.
    MacDonald MI; Osadnik CR; Bulfin L; Hamza K; Leong P; Wong A; King PT; Bardin PG
    Chest; 2019 Jul; 156(1):92-100. PubMed ID: 30978330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease.
    Thomsen M; Ingebrigtsen TS; Marott JL; Dahl M; Lange P; Vestbo J; Nordestgaard BG
    JAMA; 2013 Jun; 309(22):2353-61. PubMed ID: 23757083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of Blood Eosinophil Count to Exacerbations in Chronic Obstructive Pulmonary Disease.
    Zeiger RS; Tran TN; Butler RK; Schatz M; Li Q; Khatry DB; Martin U; Kawatkar AA; Chen W
    J Allergy Clin Immunol Pract; 2018; 6(3):944-954.e5. PubMed ID: 29153881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multi-center randomized, controlled, open-label trial evaluating the effects of eosinophil-guided corticosteroid-sparing therapy in hospitalised patients with COPD exacerbations - The CORTICO steroid reduction in COPD (CORTICO-COP) study protocol.
    Sivapalan P; Moberg M; Eklöf J; Janner J; Vestbo J; Laub RR; Browatzki A; Armbruster K; Wilcke JT; Seersholm N; Weinreich UM; Titlestad IL; Andreassen HF; Ulrik CS; Bødtger U; Nielsen TL; Hansen EF; Jensen JUS
    BMC Pulm Med; 2017 Aug; 17(1):114. PubMed ID: 28810909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood eosinophil count as a predictor of hospital length of stay in COPD exacerbations.
    Ko FWS; Chan KP; Ngai J; Ng SS; Yip WH; Ip A; Chan TO; Hui DSC
    Respirology; 2020 Mar; 25(3):259-266. PubMed ID: 31385389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood eosinophilia as a marker of early and late treatment failure in severe acute exacerbations of COPD.
    Prins HJ; Duijkers R; Lutter R; Daniels JM; van der Valk P; Schoorl M; Kerstjens HA; van der Werf TS; Boersma WG
    Respir Med; 2017 Oct; 131():118-124. PubMed ID: 28947018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.